STENOCARE A/S (STENOCARE or the “Company”) published on October 22nd the Company’s Q3-report for 2025.

The following are some key points that we have chosen to highlight in connection with the report:

• The growth trend continued – net sales increased 11% Q-Q
• Astrum 10-10 oil is being prescribed to patients in Germany
• Reaches positive EBITDA for the second consecutive quarter
• Positive operating cash flow

In conclusion, Analyst Group views STENOCARE’s Q3-25 report as another confirmation of the Company’s operational momentum and successful execution of the STENOCARE 3.0 strategy. The continued growth in Denmark demonstrates sustained market demand and recovery following previous market challenges. Meanwhile, Astrum oil, launched across three international markets, is expected to become an increasingly important growth driver in 2026 as market adoption advances. Moreover, the second consecutive quarter of positive EBITDA and operating cash flow highlights the improved cost structure and scalability of the business model. With expanding international presence and a differentiated product portfolio, STENOCARE is well positioned for continued profitable growth going forward.

Read Analyst Group’s comment on the report here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group

This is a press release from Analyst Group regarding the publication of a comment on Stenocare. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.

Läs mer på MFN